Discovery Park – 60+ years of science innovation
Pfizer acquire 80-acre site at Sandwich as part of an expansion of its Kent-based activities.
Pfizer establish an animal-feed plant at the Sandwich site and enter the UK non-prescription market for the first time.
An agricultural division was opened at the Sandwich site
Pfizer expands its Sandwich site, acquiring land for what would become known as the ‘West site’
Pfizer UK established ‘Pfizer Central Research’ with the mission to discover new pharmaceutical, chemical and agricultural products for Pfizer’s worldwide operations.
First medical use of tropical medicine, Mansil (oxamniquine).
Pfizer UK was provided with the Queen’s Awards for Technological Achievement, in recognition of the outstanding contribution made to tropical medicine by Mansil (oxamniquine).
Feldene (piroxicam), a non-steroidal anti-inflammatory drug developed jointly by the Sandwich site and Pfizer’s R&D facility in the US, was launched.
Paratect Bolus, a single dose treatment for parasitic gastroenteritis in cattle, was launched.
A third phase of buildings was completed at the Sandwich site.
The oral antifungal drug Diflucan (fluconazole) was launched.
Heart medicine Norvasc (amlodipine) was launched.
Cardura (doxazosin), a treatment for high blood pressure, was launched.
Zoloft (sertraline hydrochloride) is launched for the treatment of depression.
Dectomax (doramectin), a broad-spectrum endectocide for cattle, was launched.
Aviax (semduramicin), an ionophore anticoccidial, was launched.
Lipitor, a cholesterol lowering medicine, was launched.
Pfizer announced an investment of £109 million in a new research facility at the Sandwich site, creating 1,000 jobs.
Erectile dysfunction drug, Viagra (sildenafil), was launched.
Topical endectocide, Revolution (selamectin), was launched under the name Stronghold, as an animal anti-parasitic.
Pfizer UK received the Queen’s Award for Enterprise for the discovery and development of Viagra (sildenafil).
Vfend (voriconazole), a treatment of deadly fungal infections, was approved.
Darifenacin, a treatment for urinary incontinence, was launched.
Relpax (eletriptan HBr), a medication developed for the treatment of migraines, was launched.
Antimicrobial bovine and swine respiratory disease treatment, Draxxin (tulathromycin) was launched.
Pfizer renamed the Sandwich site ‘Discovery Park’ and put it on the market for sale.
A new chapter as Discovery Park becomes a multi-business science campus under new private ownership.
Opening of new industry liaison laboratory by Christ Church University linking academia and R&D on site
Start of work on new on-site CHP renewable energy plant
5th birthday for Discovery Park as multi-business campus with the science park passing 3,000 jobs target.